NEW YORK (GenomeWeb) – The Netherlands has made low-cost noninvasive prenatal screening available on a nationwide scale as part of a new implementation study, one of the first countries to do so. Since April 1, under the TRIDENT-2 (Trial by Dutch Laboratories for Evaluation of Noninvasive Prenatal Testing) study, all pregnant women can choose between NIPT and the first-trimester combined test (FCT) for their prenatal screening.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.